Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET

Summary

The objective of the present study is to use positron emission tomography brain imaging to investigate D3 occupancy of buspirone, an FDA-approved anxiolytic which acts as a serotonin partial agonist but has recently been identified as a D3 antagonist. It is hypothesized that clinically relevant doses of buspirone will occupy the D3 receptor.

Timeline

Start

2012-10

Primary completion

2014-06

Completion

2014-06

Drugs

Indications